Antennova to Present ATN-037 at ESMO Congress 2024
Antennova, an innovative biotech firm focused on oncology, is set to unveil the latest findings on its small molecule inhibitor, ATN-037, during a Mini Oral presentation at the European Society of Medical Oncology Congress 2024. This esteemed event will take place in Barcelona, where leading experts in the field of oncology will gather.
Highlights of the Presentation
The presentation will center on the ongoing Phase I/Ib study of ATN-037, also known as ATG-037. This inhibitor specifically targets CD73, and the study is investigating its use both as a standalone treatment and in conjunction with pembrolizumab, a prominent anti-PD-1 therapy. The goal is to assess the drug’s safety, pharmacokinetics, and the best dosage for patients dealing with advanced solid tumors.
Overview of the Study
The study, named STAMINA-01, offers significant hope for patients who have not responded well to existing therapies. ATN-037 is recognized for its strong capability to block CD73, which plays a role in tumor immune evasion. Preliminary data from the trial suggests a promising outlook regarding its effectiveness.
Important Research Details
The Mini Oral session at the ESMO Congress will provide essential insights into the performance of ATN-037:
- Abstract Number: 6067
- Presentation Number: 997MO
- Date and Time: Scheduled for September 16, 2024, at 10:50 AM CEST
Observations on Efficacy and Safety
As of early 2024, the trial has enrolled 32 patients, with dosages ranging from 20mg to 600mg of ATN-037. Notably, a disease control rate of 43.8% was reported in the monotherapy group, indicating a favorable outcome. Additionally, the combination therapy group achieved a 20% overall response rate, showcasing ATN-037's potential in treating resistant tumors.
Looking Ahead
Antennova is dedicated to advancing its research initiatives. The company is currently focused on optimizing dosage levels and expanding the trial's reach, with plans to initiate studies in Asian markets by the end of the year.
About Antennova
Antennova is a Delaware-based corporation functioning as a subsidiary of Antengene. The company is devoted to creating innovative therapies that target crucial biological mechanisms enabling tumors to evade conventional treatments. Their pipeline features a variety of promising candidates, with ATN-037 standing out as one of the leading drugs designed to tackle challenges in cancer treatment.
Frequently Asked Questions
What is ATN-037?
ATN-037 is a small molecule inhibitor that targets CD73, aimed at improving the effectiveness of cancer therapies.
What studies are being conducted on ATN-037?
A Phase I/Ib study, known as STAMINA-01, is currently assessing ATN-037 both as a monotherapy and in combination with pembrolizumab.
When will the results of the study be presented?
The latest findings will be shared at the ESMO Congress on September 16, 2024.
What types of cancers is ATN-037 targeting?
ATN-037 is being investigated for its impact on advanced solid tumors, particularly in patients with refractory or relapsed conditions.
What are the next steps for Antennova?
Antennova plans to optimize dosing and broaden its trials internationally, including efforts in Asian markets.
